Filtering by:
FDAFDA Approves Tazverik (Tazemetostat) for Epithelioid Sarcoma
The US Food and Drug Administration (FDA) has approved Tazverik (tazemetostat) to treat adults and children 16 and older with epithelioid sarcoma, a rare cancer which accounts for less than 1% of all soft tissue sarcomas.
FDA Approves Ayvakit (Avapritinib) for GIST
The US Food and Drug Administration (FDA) has approved Ayvakit (avapritinib) to treat people with advanced cases of gastrointestinal stromal tumor (GIST) that have a certain genetic mutation.
FDA Approves Padcev (Enfortumab vedotin-ejfv) for Bladder Cancer
The US Food and Drug Administration (FDA) has approved a new type of drug for certain people with bladder cancer.
2019 in Review: New Cancer Drug Approvals
In 2019, the FDA approved several new drug treatments for different cancer types. Here are the stories that made headlines on cancer.org this year.
CDC Warns Against Vaping During Lung Illness Investigation
Federal experts are investigating reports of severe lung illnesses in people who used e-cigarettes (also known as vaping).
FDA Approves Rozlytrek (Entrectinib) for Tumors With Certain Genetic Markers
The US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for adults and adolescents with tumors that test positive for NTRK gene changes, which can help cancerous tumors grow.
FDA Reveals New Ads to Warn Kids About E-Cigarettes
The US Food and Drug Administration (FDA) is launching a new series of TV ads to teach kids about the dangers of using e-cigarettes.
FDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line treatment for people with advanced head and neck cancer.
